CC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Chemours Co is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key resistance but the technical trend is still weak, recent analyst tone is mixed with several target cuts, and there is no fresh news catalyst to justify an immediate aggressive entry. Options sentiment is bullish, but for this user profile the setup is better described as a speculative hold than a clear long-term buy. If the investor is impatient and wants to act now, I would not buy at this moment.
CC closed at 19.04, essentially flat versus the prior close, but the broader signal remains bearish. The MACD histogram is -0.133 and still expanding negatively, which points to downside momentum. RSI_6 at 25.664 suggests the stock is oversold-ish but not giving a clean reversal confirmation. Moving averages are converging, indicating indecision rather than a confirmed uptrend. Price is sitting near S1 at 19.241 and above S2 at 18.408, with pivot resistance at 20.59; a decisive reclaim of the pivot would be needed to improve the trend. Overall, the chart shows weakness rather than a strong accumulation pattern.
["Several analysts still rate the stock positively, including Outperform, Buy, and Overweight calls.", "RBC and UBS recently raised targets, indicating continued belief in medium-term improvement.", "Bullish options positioning with low put-call ratios suggests traders are leaning constructive.", "Chemours has been viewed as relatively advantaged in TiO2 geography and diversification into refrigerants remains a support."]
["Mizuho lowered its price target to $25 from $30 on 2026-07-01.", "The stock dropped 5.61% in regular trading, showing near-term pressure.", "No news in the recent week, so there is no fresh catalyst driving upside.", "Technical momentum is weak, with a negative and expanding MACD histogram.", "The stock trend data suggests possible further weakness over the next month."]
No usable latest-quarter financial snapshot was provided because the data returned an error. From the analyst notes around Q1 and FY26 guidance, Chemours was seen as having maintained guidance, with expectations for second-half improvement, especially in Refrigerants and potentially higher TiO2 pricing. However, because the actual latest quarter financials are unavailable here, I cannot confirm current revenue, EPS, or margin growth from the financial data.
Recent analyst sentiment is mixed but still mostly constructive. Several firms raised price targets in April and May, with UBS, Truist, RBC, and Alembic turning more positive or maintaining bullish ratings. However, Mizuho cut its target on 2026-07-01 to $25 from $30, which is the newest move and slightly softens the near-term outlook. Overall, Wall Street remains more positive than negative, but the view is not strong enough to call CC a clear buy today. Pros: multiple Buy/Outperform ratings and several target increases. Cons: the latest target cut, weaker near-term price action, and no fresh catalyst.
